---
figid: PMC10377333__biomedicines-11-01988-g001
figtitle: 'Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for
  Laboratory Determination in Tumor Immunotherapy'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10377333
filename: biomedicines-11-01988-g001.jpg
figlink: /pmc/articles/PMC10377333/figure/biomedicines-11-01988-f001/
number: F1
caption: Metabolism of tryptophan and the action of IDO (indoleamine 2,3-dioxygenase)
  inhibitors in the tryptophan metabolic pathway. In vivo, ~95% of L-tryptophan is
  catabolized via IDO in the form of kynurenine degradation products. Additional enzymatic
  metabolites in the pathway promote immune suppression. IDO inhibitors primarily
  compete with tryptophan by binding to the catalytic domain of IDO or non-competitive
  mechanisms to affect tryptophan metabolism, thereby exerting an inhibitory effect
  on IDO. IDO1, indoleamine 2,3-dioxygenase 1; IDO2, indoleamine 2,3-dioxygenase 2;
  TDO, tryptophan dioxygenase; FAMID, formamidase; KATs, kynurenine aminotransferases;
  KMO, kynurenine 3-monooxygenase; KYNU, kynureninase; 3HAAO, 3-hydroxyanthranilic
  acid dioxygenase; QPRT, quinolinic-acid phosphoribosyl transferase; NAD+, nicotinamide
  adenine dinucleotide; GCN2, general control nondepressible-2; mTORC1, mammalian
  target of rapamycin complex 1; AhR, aryl hydrocarbon receptor; Treg cells, regulatory
  T cells.
papertitle: 'Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for
  Laboratory Determination in Tumor Immunotherapy.'
reftext: Pengbo Yang, et al. Biomedicines. 2023 Jul;11(7):1988.
year: '2023'
doi: 10.3390/biomedicines11071988
journal_title: Biomedicines
journal_nlm_ta: Biomedicines
publisher_name: MDPI
keywords: indoleamine 2,3-dioxygenase | kynurenine pathway | immune response | biomarker
  | enzymatic activity | IDO inhibitors
automl_pathway: 0.920754
figid_alias: PMC10377333__F1
figtype: Figure
redirect_from: /figures/PMC10377333__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10377333__biomedicines-11-01988-g001.html
  '@type': Dataset
  description: Metabolism of tryptophan and the action of IDO (indoleamine 2,3-dioxygenase)
    inhibitors in the tryptophan metabolic pathway. In vivo, ~95% of L-tryptophan
    is catabolized via IDO in the form of kynurenine degradation products. Additional
    enzymatic metabolites in the pathway promote immune suppression. IDO inhibitors
    primarily compete with tryptophan by binding to the catalytic domain of IDO or
    non-competitive mechanisms to affect tryptophan metabolism, thereby exerting an
    inhibitory effect on IDO. IDO1, indoleamine 2,3-dioxygenase 1; IDO2, indoleamine
    2,3-dioxygenase 2; TDO, tryptophan dioxygenase; FAMID, formamidase; KATs, kynurenine
    aminotransferases; KMO, kynurenine 3-monooxygenase; KYNU, kynureninase; 3HAAO,
    3-hydroxyanthranilic acid dioxygenase; QPRT, quinolinic-acid phosphoribosyl transferase;
    NAD+, nicotinamide adenine dinucleotide; GCN2, general control nondepressible-2;
    mTORC1, mammalian target of rapamycin complex 1; AhR, aryl hydrocarbon receptor;
    Treg cells, regulatory T cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - DLX3
  - TDO2
  - IDO2
  - KMO
  - KYNU
  - EIF2AK4
  - MTOR
  - RPTOR
  - AHR
  - QPRT
  - BMS-986205
  - PF-06840003
  - L-tryptophan
  - Trp
  - N-formyl kynurenine
  - Kynurenine
  - 3-hydroxykynurenine
  - KYNU
  - 3-hydroxyanthranilic acid
  - Kynurenic acid
  - Aminocarboxymuconic semialdehyde
  - Xanthurenic acid
  - Quinolinic acid
  - NAD
  - semialdehyde
---
